Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ceapro Inc (OP: CRPOF )

0.2003 UNCHANGED
Streaming Delayed Price Updated: 12:05 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2003
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2003
Today's Range 0.2003 - 0.2003
52wk Range 0.1146 - 0.4269
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
From Ceapro Inc.
Via GlobeNewswire

Performance

YTD
+26.13%
+26.13%
1 Month
+8.56%
+8.56%
3 Month
+64.45%
+64.45%
6 Month
+8.56%
+8.56%
1 Year
-53.08%
-53.08%

More News

Read More
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
From Ceapro Inc.; Aeterna Zentaris Inc.
Via GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
From Ceapro Inc.
Via GlobeNewswire
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
From Ceapro Inc.
Via GlobeNewswire
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Results of 2023 Shareholders’ Meeting
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
From Ceapro Inc.
Via GlobeNewswire
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
From Ceapro Inc.
Via GlobeNewswire
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
From Ceapro Inc.
Via GlobeNewswire
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Via ACCESSWIRE
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
From Ceapro Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.